Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
A balance between the activation of the inflammatory macrophages and suppression of the anti-inflammatory macrophages in the kidney may play a pivotal role in kidney stone formation. These macrophage-derived mediators may have potential as biomarkers to reflect the urinary stone risk, according to a new study from Japan, which was recently presented at the recent 2nd Meeting of the EAU Section of Urolithiasis and received Clinical Research Award.
Compared to that of control subjects, the urine from individuals with a history of kidney stone formation showed significantly increased levels of the inflammatory chemokines GRO and CXCL1, and significantly decreased levels of IL-4, an anti-inflammatory cytokine involved in macrophage migration. According to Dr. Dr. Atsushi Okada, of Nagoya City University in Japan, this research deals with some very important issues in the field of urolithiasis.
"To date, the risk evaluation and the preventive index of kidney stone formation have been dependent on urinary inorganic matter such as calcium, phosphorus, magnesium, uric acid, oxalate and citrate. However, stone formers don't often show such an abnormality," he explained.
"In a series of preceding studies, we examined organic substance in kidney stones, such as protein from kidney tissue, and revealed that stone matrix and genetic environment of renal tubular cells are as important as urinary inorganic condition for kidney stone formation."
"In the past we have also shown that in mice, certain regulatory mechanisms protect against urinary calcium oxalate stone formation, and that these mechanisms may be mediated by anti-inflammatory Type 2 macrophages (M2s). However, regulatory roles of M2 macrophages in urinary stone formation in humans have not been studied."
This latest study aimed to identify urinary M2 macrophage-associated markers, by performing multiplex urinalysis in individuals prone to developing calcium oxalate kidney stones. The authors were able to observe that stone-formers had a higher level urinary M1 markers, whereas non-stone formers had a higher level of M2 markers.
Dr. Okada believes that this study may have pronounced implications for clinical practice.
"If the usefulness of these macrophage markers is established, it will be possible to evaluate kidney stone risk not only through inorganic but also some organic substances. Furthermore, these results may lead to the development of new therapeutic drugs for kidney stone formation to control macrophage function.
A. Okada et al, Macrophage-derived cytokines and chemokines may be novel markers to predict calcium oxalate stone formation in humans, Abstract E88, 2nd Meeting of the EAU Section of Urolithiasis.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Urology / Nephrology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
European Association of Urology. "Macrophage-derived mediators may have potential as biomarkers for urinary stone risk." Medical News Today. MediLexicon, Intl., 3 Oct. 2013. Web.
7 Dec. 2013. <http://www.medicalnewstoday.com/releases/266885>
European Association of Urology. (2013, October 3). "Macrophage-derived mediators may have potential as biomarkers for urinary stone risk." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/266885.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.